Article

Cytoplasmic ezrin and moesin correlate with poor survival in head and neck squamous cell carcinoma.

Department of Epidemiology and Population Health, Albert Einstein College of Medicine and Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.
Head and Neck Pathology 01/2012; 6(2):232-43. DOI:10.1007/s12105-011-0328-1 pp.232-43
Source: PubMed

ABSTRACT Members of the 4.1 superfamily of proteins, including ezrin, moesin, merlin, and willin regulate many normal physiologic processes such as cellular shape, motility, and proliferation. In addition, they contribute both to tumor development and tumor progression. We reported previously that strong cytoplasmic ezrin expression was independently associated with poorer patient survival. One hundred and thirty-one histologically confirmed primary head and neck squamous cell carcinomas were examined prospectively for cancer progression and survival at a large health care center in the Bronx, NY, USA. Immunohistochemical analysis of ezrin, moesin, merlin, and willin expression in tissue microarray samples of primary head and neck squamous cell carcinoma revealed a significant association of increased cytoplasmic ezrin with poor cancer survival. Global RNA analyses suggest that cancers with high cytoplasmic ezrin have a more invasive phenotype. This study supports our previous findings associating cytoplasmic ezrin with more aggressive behavior and poorer outcome and indicates the need for a multi-institutional study to validate the use of cytoplasmic ezrin as a biomarker for treatment planning in head and neck squamous cell carcinoma.

0 0
 · 
0 Bookmarks
 · 
30 Views
  • Article: Differential expression of the microspike-associated protein moesin in human tissues.
    R Schwartz-Albiez, A Merling, H Spring, P Möller, K Koretz
    [show abstract] [hide abstract]
    ABSTRACT: The protein moesin is a member of a gene family consisting of talin, ezrin, radixin, protein 4.1., and merlin. Proteins of this family are associated to the submenbranous cytoskeleton. Using monoclonal antibody 38/87 directed against moesin in immunochemical analysis, the 78 kDa moesin protein was demonstrated in endothelial cells and in cells of carcinoma, mesothelioma and lymphoid origin. Moesin was metabolically labeled by [32P]orthophosphate and reacted with an antibody against phosphotyrosine. Moesin also contains carbohydrate residues as demonstrated by immunostainings of digoxigenin-labeled sugar residues. The antibody 38/87 in comparison to antisera against radixin and ezrin was applied in immunohistological stainings on various human tissues. As a prominent feature, moesin as strongly expressed in endothelium of vessels in contrast to radixin and ezrin. Moesin but not radixin was observed in T and B lymphocytes. Further, moesin was expressed in basal layers of squamous epithelium and glandular ducts and lymphocytes. Subcellular expression of moesin was studied on cultured human endothelial cells of umbilical cord veins and the mesothelioma cell line CH3LC by confocal laser scanning microscopy. In subconfluently growing cells moesin showed a characteristic expression on extending microspikes at the basal cell level. Moesin was coexpressed with actin in the cortical cytoskeleton and on microspikes but not in stress fibers. The differential cellular expression of moesin and its pronounced occurrence on microspikes of growing cells support the possibility that moesin is a protein involved in plasma membrane-cytoskeleton interactions in specialized tissues.
    European Journal of Cell Biology 08/1995; 67(3):189-98. · 2.81 Impact Factor
  • Article: Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers.
    Jiro Fujimoto, Ikumi Aoki, Hiroshi Toyoki, Sufia Khatun, Eriko Sato, Hideki Sakaguchi, Teruhiko Tamaya
    [show abstract] [hide abstract]
    ABSTRACT: ETS-1 has been identified as a proto-oncogene and a transcription factor for tumor angiogenesis, which is essential for the growth, invasion and metastasis of solid tumors. The aim is to investigate the clinical implications of ETS-1 expression in peritoneal metastatic lesions of ovarian cancers. In primary tumors and peritoneal metastatic lesions from 30 patients with stage III ovarian cancers, ETS-1 histoscores and ets-1 mRNA levels were determined by immunohistochemistry and competitive RT-PCR-Southern blot analysis using recombinant RNA, respectively. Immunohistochemical staining revealed that ETS-1 was expressed in the cancer cells and vascular endothelial cells. ETS-1 histoscores in the endothelial cells and ets-1 mRNA levels were significantly (p < 0.05) increased in 20 of 30 peritoneal metastatic lesions of ovarian cancers. There was a significant correlation between microvessel counts (MVCs) and ETS-1 histoscores in the endothelial cells (p < 0.001) and between MVCs and ets-1 mRNA levels in the primary tumor and the peritoneal metastatic lesion of ovarian cancers (p < 0.001). Furthermore, the 24-month survival rate of patients with significantly increased ets-1 mRNA level (2/20, 10%) was significantly (p < 0.01) lower than that of patients with no change in the level (6/10, 60%) from the primary tumor to the peritoneal metastatic lesion. ETS-1 might be associated with peritoneal metastasis dominantly as an angiogenic mediator and additionally as an oncogene product to activate tumor invasion in ovarian cancers.
    Oncology 01/2004; 66(5):420-8. · 2.27 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

aggressive behavior
 
cancer progression
 
cellular shape
 
cytoplasmic ezrin
 
Global RNA analyses
 
Immunohistochemical analysis
 
invasive phenotype
 
large health care center
 
neck squamous cell carcinoma
 
neck squamous cell carcinomas
 
normal physiologic processes
 
poor cancer survival
 
poorer outcome
 
poorer patient survival
 
significant association
 
strong cytoplasmic ezrin expression
 
tissue microarray samples
 
treatment planning
 
tumor development
 
tumor progression